Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic inactivation of BCL6B , a novel functional tumour suppressor for gastric cancer, is associated with poor survival

13 Sept 2011

Abstract excerpt

OBJECTIVE: Using genome-wide promoter methylation assay, B cell CLL/lymphoma 6 member B (BCL6B) was found to be preferentially methylated in cancer. A study was undertaken to examine the epigenetic regulation, biological function and clinical significance of BCL6B in gastric cancer (GC). METHODS: BCL6B promoter methylation was evaluated by combined bisulfite restriction analysis and sequencing. The biological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Histone Deacetylase Inhibitors Research
Share to NF-κB Signaling Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21917650
DOI: 10.1136/gutjnl-2011-300411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic inactivation of BCL6B , a novel functional tumour suppressor for gastric cancer, is associated with poor survivalPMID 21917650Read ↗

Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FUSemantic proximity Read ↗

MYBL2 promotes cell proliferation and inhibits cell apoptosis via PI3K/AKT and BCL2/BAX/Cleaved-caspase-3 signaling pathway in gastric cancer cellsSemantic proximity Read ↗

Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.Semantic proximity Read ↗

Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.Semantic proximity Read ↗

Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 casesSemantic proximity Read ↗

Epstein–Barr virus-associated gastric cancer: A distinct subtypeSemantic proximity Read ↗

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphomaSemantic proximity Read ↗

Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting <i>BAD</i> -Mediated <i>caspase-3</i> -Dependent ApoptosisSemantic proximity Read ↗

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaSemantic proximity Read ↗

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.Semantic proximity Read ↗

EBV-miR-BART5-5p regulates RORA to promote proliferation and migration of gastric cancer cellsSemantic proximity Read ↗

The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.